BridgeBio Pharma, Inc. Annual Net Cash Provided by (Used in) Financing Activities in USD from 2017 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
BridgeBio Pharma, Inc. quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from 2017 to 2023.
  • BridgeBio Pharma, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2024 was $280M, a 86.1% increase year-over-year.
  • BridgeBio Pharma, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $452M.
  • BridgeBio Pharma, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was -$13.1M, a 102% decline from 2021.
  • BridgeBio Pharma, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2021 was $736M, a 64.7% increase from 2020.
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $452M +$465M Jan 1, 2023 Dec 31, 2023 10-K 2024-02-22
2022 -$13.1M -$750M -102% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-22
2021 $736M +$289M +64.7% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-22
2020 $447M +$48.4M +12.1% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-23
2019 $399M -$103M -20.5% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-25
2018 $502M +$389M +344% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-25
2017 $113M Jan 1, 2017 Dec 31, 2017 10-K 2020-03-03
* An asterisk sign (*) next to the value indicates that the value is likely invalid.